About this trial
Hydra-IT is a multicenter observational study aim to collect clinical, procedural and follow-up data and evaluate the short, medium and long term results of Hydra TAVI System in patient with severe aortic stenosis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with severe symptomatic native aortic valve stenosis and candidates for the TAVI procedure based on the evaluation of the Heart Team
Ability to understand and provide informed consent for inclusion in the study
Disqualifiers
Contraindication to TAVI: e.g. evidence of intracardiac mass, thrombus or vegetation, endocarditis.
Refusal by the patient to participate in the study
High probability of non-adherence to required follow-ups
Trial population
Patient with severe aortic valve stenosis
Trial design
Case-only
Prospective
Treatments tested in this trial
Hydra Transcatheter Aortic Valve System
DeviceThe Hydra device is self-expanding transcatheter aortic valve consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
Treatment groups
Trial outcomes
Primary outcomes
Cardiovascular mortality
Secondary outcomes
All-cause mortality
Cardiovascular mortality, valve-related mortality, and non-cardiovascular mortality
All stroke
Disabling and non-disabling stroke
Disabling stroke
Myocardial infarction
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Sahajanand Medical Technologies Limited
Lead sponsor
Clinica Di Montevergine
Collaborator